Page last updated: 2024-09-05

sorafenib and cap1-6d

sorafenib has been researched along with cap1-6d in 1 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (cap1-6d)	Trials (cap1-6d)	Recent Studies (post-2010) (cap1-6d)
6,520	730	5,251	20	2	13

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Choi, I; Kim, KM; Kim, N; Kim, S; Lee, JY; Lee, SY; Rhu, HC; Seo, HR; Song, Y	1

Other Studies

1 other study(ies) available for sorafenib and cap1-6d

Article	Year
Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma. Chemico-biological interactions, 2022, Sep-25, Volume: 365 Topics: Adenylyl Cyclases; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Oligopeptides; Pyrimidinones; Sorafenib	2022

Article

Year

Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma.

Chemico-biological interactions, 2022, Sep-25, Volume: 365

Topics: Adenylyl Cyclases; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Oligopeptides; Pyrimidinones; Sorafenib

2022